NYSEHealth CareHealth Care EquipmentS&P MidCap 400S&P SmallCap 600
$224.41
+4.43 (+2.01%)
Close of Nov 06, 2026 · end-of-day data
GKOS 8-K filings in 2025
Every material Form 8-K Glaukos filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Glaukos reported third-quarter 2025 net sales of $133.5 million, up 38% from a year earlier, and cut its net loss to $16.2 million from $21.4 million. The company raised its 2025 net sales guidance to $490 million to $495 million and gave preliminary 2026 net sales guidance of $600 million to $620 million. For shareholders, revenue growth and the higher guidance are offset by the company still posting a GAAP net loss for the quarter.
Q3 2025 net sales were $133.5 million, up 38% from $96.7 million in Q3 2024 (37% on a constant currency basis).
Q3 2025 net loss was $16.2 million, or $0.28 per diluted share, versus a net loss of $21.4 million, or $0.39 per share, in Q3 2024.
2025 net sales guidance was raised to $490 million to $495 million, from $480 million to $486 million previously.
Preliminary 2026 net sales guidance is $600 million to $620 million; the company had $277.5 million in cash, short-term investments and restricted cash and no debt as of September 30, 2025.
Glaukos reported record second-quarter 2025 net sales of $124.1 million, up 30% from $95.7 million a year earlier, and a net loss of $19.7 million, or $0.34 per diluted share, versus a $50.5 million loss ($1.00 per share) in the prior-year quarter. The company raised its full-year 2025 net sales guidance to $480 million to $486 million from $475 million to $485 million, and ended the quarter with $278.6 million in cash, short-term investments and restricted cash and no debt.
Q2 2025 net sales of $124.1 million, up 30% from $95.7 million in Q2 2024
Net loss of $19.7 million, or $0.34 per diluted share, compared with $50.5 million, or $1.00 per share, in Q2 2024
2025 net sales guidance raised to $480 million to $486 million from $475 million to $485 million
Cash, short-term investments and restricted cash of $278.6 million at June 30, 2025, with no debt
Glaukos reported first quarter 2025 results on April 30, 2025, with net sales of $106.7 million, up 25% from $85.6 million a year earlier. The net loss narrowed to $18.1 million, or $0.32 per diluted share, from $40.8 million, or $0.82 per share, in the first quarter of 2024. The company reaffirmed its 2025 net sales guidance of $475 million to $485 million.
Q1 2025 net sales were $106.7 million, up 25% reported and 26% on a constant currency basis.
U.S. Glaucoma net sales were $59.1 million, up 41%, driven by iDose TR.
Net loss was $18.1 million, or $0.32 per diluted share, versus $40.8 million, or $0.82 per share, a year earlier.
The company ended the first quarter with about $303.4 million in cash, short-term investments and restricted cash, and no debt.
Glaukos reported fourth-quarter 2024 net sales of $105.5 million, up 28% from a year earlier, and full-year 2024 net sales of $383.5 million, up 22%. The company also introduced 2025 net sales guidance of $475 million to $485 million, while its GAAP net loss narrowed to $33.6 million from $36.8 million a year earlier.
Q4 2024 net sales were $105.5 million, up 28% year over year, and GAAP net loss was $33.6 million, or $0.60 per diluted share, versus $0.75 a year earlier.
FY 2024 net sales were $383.5 million, up 22%; GAAP net loss was $146.4 million, or $2.77 per diluted share.
Q4 2024 GAAP gross margin was approximately 73%, compared with approximately 77% in Q4 2023.
The company introduced 2025 net sales guidance of $475 million to $485 million and ended 2024 with approximately $324 million in cash, short-term investments and restricted cash, and no debt.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Glaukos filing is on SEC EDGAR ↗. 8-K briefs of other companies →